How did URGN's Q3 2024 earnings surprise impact its stock?

UroGen Pharma's (URGN) Q3 2024 earnings surprise had a negative impact on its stock, as the company reported an earnings per share (EPS) surprise of $0.27, which was followed by a decline of 2.83% in its stock price.

|code|Ticker|Name|Date|Revenue Surprise|Percentage Change|market_code|
|---|---|---|---|---|---|---|
|URGN|URGN.O|UroGen Pharma|20231002||-2.2841|185|
|URGN|URGN.O|UroGen Pharma|20231003||1.3148|185|
|URGN|URGN.O|UroGen Pharma|20231004||-3.5328|185|
|URGN|URGN.O|UroGen Pharma|20231005||1.2706|185|
|URGN|URGN.O|UroGen Pharma|20231006||1.107|185|
|URGN|URGN.O|UroGen Pharma|20231009||-2.3358|185|
|URGN|URGN.O|UroGen Pharma|20231010||2.7653|185|
|URGN|URGN.O|UroGen Pharma|20231011||-2.0364|185|
|URGN|URGN.O|UroGen Pharma|20231012||-2.8953|185|
|URGN|URGN.O|UroGen Pharma|20231013||0.1529|185|